Gemcitabine-based chemotherapy in colon squamous cell carcinoma: A case report and literature review

Squamous cell carcinoma (SCC) originating from the colon is rare. In terms of its clinicopathological characteristics, this type of cancer has been reported to be more aggressive and have a worse prognosis compared with adenocarcinoma. We herein present a successful therapeutic approach applying neo...

Full description

Saved in:
Bibliographic Details
Published in:Molecular and clinical oncology 2017-04, Vol.6 (4), p.561-565
Main Authors: Zhao, Shufen, Guo, Jing, Sun, Libin, Lv, Jing, Qiu, Wensheng
Format: Article
Language:English
Subjects:
Abdomen
Cancer
Case reports
Case studies
Chemotherapy
Clinical medicine
Colon cancer
Colorectal cancer
Complications and side effects
Diagnosis
Dosage and administration
Drug therapy
Gemcitabine
Health aspects
Lymphatic system
Medical prognosis
Metastasis
Oncology
Pathology
Patients
Prognosis
Radiation therapy
Squamous cell carcinoma
Studies
Surgery
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Squamous cell carcinoma (SCC) originating from the colon is rare. In terms of its clinicopathological characteristics, this type of cancer has been reported to be more aggressive and have a worse prognosis compared with adenocarcinoma. We herein present a successful therapeutic approach applying neoadjuvant and adjuvant gemcitabine-based chemotherapy in a patient with colon SCC. A 58-year-old male patient received two cycles of neoadjuvant chemotherapy with a regimen including gemcitabine, oxaliplatin and capecitabine, followed by radical excision and six cycles of adjuvant chemotherapy. Contrast-enhanced computed tomography and serum tumor markers were used for reassessment and evaluation was based on the World Health Organization criteria. Following neoadjuvant chemotherapy, the mass had shrunk and the patient was classed as having stable disease. Surgery and adjuvant chemotherapy were then performed and the patient had achieved a progression-free survival of 10 months when this report was submitted. Therefore, gemcitabine may be a treatment option for colon SCC in the neoadjuvant and/or adjuvant chemotherapy setting.
ISSN:2049-9450
2049-9469
DOI:10.3892/mco.2017.1178